Table 2.

A selection of clinical trials testing novel strategies to target MET altered NSCLC.

NCT Number	Gene Alteration	Experimental Drug	Phase	Study Design	Current Status
NCT05015608	MET amplification	Savolitinib	3	Randomized: savolitinib + osimertinib vs. pemetrexed + cisplatin/carboplatin	Recruiting
NCT04338243	MET amplification	Glumetinib	1/2	Single group assignment	Unknown
NCT02435121	MET amplification	SAR125844	2	Single group assignment	Completed
NCT02544633	MET mutation, amplification	MGCD265	2	Single group assignment	Completed
NCT03175224	METex14, amplification, fusion	APL-101	1/2	Single group assignment	Recruiting
NCT04270591	MET mutation, amplification	Glumetinib	1/2	Single group assignment	Active, not recruiting
NCT02648724	MET amplification	Sym015	1/2	Single group assignment	Completed
NCT03539536	MET amplification	Telisotuzumab vedotin	2	Single group assignment	Recruiting
NCT05163249	MET amplification	Savolitinib	2	Randomized: osimertinib ± savolitinib	Not yet recruiting
NCT03993873	MET mutation, amplification	TPX-0022	1/2	Single group assignment	Recruiting